Inflation Reduction Act
We offer comprehensive support for biopharma teams navigating Medicare drug price negotiation, from evidence strategy through post-negotiation commercialization.
Why choose us?
Strategic insights, backed by data
The Inflation Reduction Act has changed how life sciences firms plan, price, and commercialize products under Medicare.
Since the law’s inception, we’ve conducted 200+ IRA projects across 30+ distinct clients and stakeholders, driving negotiation for 25 products. Our end-to-end support has delivered an estimated median maximum fair price of +12% versus -31% for other negotiated products in those baskets.
How we work
We offer tailor-made support across the full product lifecycle, from early clinical development through loss of exclusivity, including generic/biosimilar entry.
Investment support
Policy education sessions
Portfolio assessments
Policy analytics and advocacy strategy
Investment assessment tools and frameworks
Individual asset assessments
Evidence submission and negotiation process
Negotiation forecast
Negotiation strategy development
ICER support
Education and organization readiness assessments
ICR and dossier development
Evidence generation
Evidence and value assessment
Counteroffer support
Commercial strategy
Pricing and contracting strategy
Gross-to-net modeling
Loss of exclusivity strategy
Pharmacy benefit
Competitor analysis
MFP effectuation strategy
Medical benefit
Channel strategy
Our approach
A customized approach for every negotiation
Avalere Health triangulates our clients’ priorities, objectives, and product’s stage of development with external considerations such as market dynamics, therapeutic area, and the policy environment to meet specific client needs.
We tailor our wide array of offerings to help clients shape the policy and market environment, advance evidence development, assess risk and key impacts, develop strategic plans, and ultimately execute their response to negotiation selection.
Who we help
Life sciences companies
Health plans
Trade organizations
Offerings
Environmental monitoring
Primary research and KOL validation
Evidence submission and support
Portfolio and engagement strategy
Scenario planning and forecasting
Evidence generation and modeling
Value and evidence assessment
Impact and risk assessment
Our work
How we have helped clients
Case study
Establishing an Inflation Reduction Act evidence roadmap to navigate shifting HEOR needs
A manufacturer sought to integrate Inflation Reduction Act-specific evidence needs into its existing evidence generation planning processes to ensure earlier preparation for directly negotiated and indirectly impacted products. Avalere provided a comprehensive and tailored evidence planning guide for the client apply across its portfolio to ensure IRA evidence readiness.
Discover moreCase study
Mock negotiation panel and counteroffer preparation
A manufacturer sought support in understanding how CMS would conduct its negotiation meetings and the CMS staff and their roles, as well as anticipating questions to inform their negotiations strategy. Avalere Health helped the client set a simulated maximum fair price and identify gaps in evidence that could be filled before negotiation.
Discover moreCase study
Risk assessment and impact on pipeline asset strategy
A client engaged Avalere Health to determine Inflation Reduction Act-related risk exposure across 11 priority pipeline assets to understand the effects on pricing, reimbursement, competitor responses, and payer contracting pressure, among other key assumptions defining future market conditions. The client leveraged the analysis to inform a series of key strategic decisions on investment, R&D and risk mitigation.
Discover more
Our people
